Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
← catalyst calendarNCT06921785 · readout in 940 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
1,220estimated
Sites
220
Countries
Australia, Brazil, Canada +17
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-06 | actual | When the study began enrolling |
| Primary completion | 2029-03-16 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-03-15 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hepatocellular Carcinoma
Interventions
- Drug: Tremelimumab
- Drug: Rilvegostomig
- Drug: Bevacizumab
- Drug: Atezolizumab
Primary outcome
what the primary-completion date above is the date OFTo demonstrate the efficacy of Arm A relative to Arm C by assessment of OS in participants with advanced HCC
measured Up to approximately 6 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed